The Future Directions Across the Spectrum of Breast Cancer

CME Activities

• LIVE EVENT
  Evolving Paradigms in Hormone Receptor-Positive Breast Cancer: The Rise of Antibody-Drug Conjugates

  FRIDAY, 30 OCTOBER 2023

  Madrid, Spain

  REGISTER NOW
• How to Treat HER2-Low Metastatic Breast Cancer: The Expert Approach
  Medscape Education, August 2023
  Do you know how to discuss new disease subcategories such as HER2-low with patients? Especially those confirmed as HER2-negative in the past?
  0.25 CME

  0.25 ABIM MOC
• Shifting Paradigms in the Management of HR-Positive/HER2-Negative Metastatic Breast Cancer: Expert Insights
  Medscape Education, August 2023
  Are you up to date on the latest developments in HR+/HER2− mBC? Do you understand the mechanisms of action of emerging agents?
  0.50 CME

  0.50 ABIM MOC
• Latest Advances in Systemic Treatment for Breast Cancer: Evidence and Implications
  Medscape Education, June 2023
  Are you up to date with developments in breast cancer? Join the specialists for the data most recently presented at the American oncology meeting.
  0.75 CME

  0.75 ABIM MOC
• Managing Adverse Events of Novel Antibody-Drug Conjugates in Breast Cancer
  Medscape Education, June 2023
  Do you know the best practice strategies for preventing and managing adverse events with antibody-drug conjugates (ADCs) in breast cancer?
  0.25 CME

  0.25 ABIM MOC
• Expert Exchange: Clinical Implications of the Latest Advances in Metastatic Breast Cancer
  Medscape Education, June 2023
  Do you know how to personalize treatment for your patients with metastatic breast cancer (mBC)? How can you incorporate emerging treatment strategies?
  0.50 CME

  0.50 ABIM MOC
• Clinical Updates in Hereditary Breast Cancer: Highlights From Vienna 2023
  Medscape Education, March 2023
  Do you know how to select the optimal treatment for a patient with early breast cancer who is eligible for PARP inhibitor and CDK4/6 inhibitor therapy?
  0.25 CME
• Optimizing Adjuvant Treatment of Early Breast Cancer: Where Are We Today?
  Medscape Education, March 2023
  PARP inhibitors, CDK4/6 inhibitors, immunotherapy, and SERDS: Can you select optimal treatments for early breast cancer (EBC)? And what might be the consensus at St. Gallen?
  0.50 CME
• HER2 Testing in 2023: Case Studies for Pathologists
  Medscape Education, March 2023
  Are you up to date with the latest guidance and best practices in breast cancer human epidermal growth factor receptor 2 (HER2) testing? Learn more here!
  1.00 CME
• The Evolution of HER2 Therapies in Breast Cancer
  Medscape Education, November 2022
  Did you know that human epidermal growth factor receptor 2 (HER2) was among the first targets in breast cancer? Join the experts for the history of HER2 therapies and future outlook.
  0.75 CME
• Two Decades of HER2 Targeting: The Unfinished Revolution in Breast Cancer
  Medscape Education, November 2022
  Did you know we can tailor human epidermal growth factor receptor 2 (HER2) therapy to patient’s risk profile without compromising outcomes?
  1.25 CME
• The Pathologist's Role in Improving Outcomes for Patients With HER2-Expressing Breast Cancer
  Medscape Education, October 2022
  Did you know that up to 55% of breast cancers have low human epidermal growth factor receptor 2 (HER2) expression? Join the experts in discussing implications of HER2-low in breast cancer.
  0.50 CME
• The Surgical Voice in Early-Stage High-Risk Breast Cancer
  Medscape Education Oncology, October 2022
  Do you know which team member plays the most pivotal role in ensuring early-stage breast cancer patients receive vital gene testing?
  0.25 CME
• Breast Cancer Expert Voices from Paris
  Medscape Education, October 2022
  Are you up to date with the latest breast cancer data? Or looking to further understand its implications? Watch these expert perspectives for insight.
  0.50 CME

SABCS Conference 360

• Management of HR+ Breast Cancer: Changing Paradigms by Maximizing the Clinical Potential of Therapeutic Targets
  Medscape Education, February 2023
  Are you aware of the clinical potential of novel therapeutic targets and emerging evidence for hormone receptor-positive (HR+) breast cancer?
  1.25 CME

  1.25 ABIM MOC
• Breast Cancer Therapies: Interrogating the Data From San Antonio 2022
  Medscape Education, January 2023
  Did you know that the efficacy of SERDs in ER+/HER2- metastatic breast cancer differs according to length of prior CDK4/6 inhibitor treatment?
  0.50 CME
• Breast Cancer Snapshots From San Antonio 2022
  Medscape Education, December 2022
  Are you aware of the latest clinical research devoted to improving diagnosis and treatment of breast cancer?
  0.50 CME
• A Preview of the San Antonio 2022 Meeting for Breast Cancer
  Medscape Education, November 2022
  What are the anticipated highlights for the upcoming SABCS 2022 meeting? Join Dr Müller for expert insights on the latest developments.